Efficacy and Safety of Carrimycin Tablets in HLH Patients With Carbapenem-resistant Infections

NANot yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 30, 2023

Primary Completion Date

August 30, 2026

Study Completion Date

December 30, 2026

Conditions

Carbapenem Resistant Bacterial InfectionHemophagocytic Lymphohistiocytoses

Interventions

DRUG

Carrimycin tablets

Carrimycin tablets are administered 400mg a day orally for 7 days.

Trial Locations (1)

Beijing Friendship Hospital, Capital Medical University, Beijing

All Listed Sponsors

lead

Beijing Friendship Hospital

OTHER

NCT05988177 - Efficacy and Safety of Carrimycin Tablets in HLH Patients With Carbapenem-resistant Infections | Biotech Hunter | Biotech Hunter